Cargando…
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
BACKGROUND: Amyloid transthyretin (ATTR) amyloidosis is caused by the systemic deposition of transthyretin molecules, either normal (wild‐type ATTR, ATTRwt) or mutated (variant ATTR, ATTRv). ATTR amyloidosis is a disease with a severe impact on patients’ quality of life (QoL). Nonetheless, limited a...
Autores principales: | Aimo, Alberto, Rapezzi, Claudio, Perfetto, Federico, Cappelli, Francesco, Palladini, Giovanni, Obici, Laura, Merlini, Giampaolo, Di Bella, Gianluca, Serenelli, Matteo, Zampieri, Mattia, Milani, Paolo, Licordari, Roberto, Teresi, Lucio, Ribarich, Nicolò, Castiglione, Vincenzo, Quattrone, Filippo, De Rosis, Sabina, Vergaro, Giuseppe, Panichella, Giorgia, Emdin, Michele, Passino, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596396/ https://www.ncbi.nlm.nih.gov/pubmed/33982288 http://dx.doi.org/10.1111/eci.13598 |
Ejemplares similares
-
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022) -
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021) -
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022) -
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023) -
Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)